This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

27 Aug 2021

Cipla and Kemwell to form joint venture targeting respiratory biosimilars market

The agreement is expected to accelerate Cipla’s global lung leadership agenda

Cipla has announced a joint venture agreement with biopharmaceutical CDMO Kemwell Biopharma to develop, manufacture and commercialise biosimilars for global markets.

To accomplish this, the parties will create a joint venture company with an aim to enter the respiratory biosimilars space.

By pooling resources, the joint venture will leverage Cipla and Kemwell’s complementary strengths for end-to-end product development, clinical development, regulatory filings, manufacturing and commercialisation of biopharmceutical products.

The companies expect Cipla’s respiratory expertise combined with Kemwell’s capabilities in biologics will accelerate bringing cost-effective biopharmaceutical products to market.

Umang Vohra, Managing Director & Global Chief Executive Officer of Cipla, said the agreement is in line with its aspiration to become a global lung leader.

Mentioned Companies
Kemwell Biopharma
View company profile
Cipla Ltd
View company profile

Related News